Clinical Research And Development Service Articles & Analysis: Older
15 news found
It has been documented that liposome encapsulation is an enhancement strategy that can be developed alongside emulsions, microemulsions and biopolymer-based systems to develop newer and better formulations in the food field. ...
The two companies collaborated with precision medicine clinical research organization (CRO) Precision for Medicine, which contributes its state-of-the-art, CAP-accredited, CLIA-certified laboratory services to Boundless Bio’s POTENTIATE Phase 1/2 clinical trial by successfully validating a proprietary workflow to process ...
This advancement allows researchers and developers to leverage the power of liposome technology for a wider range of applications. ...
The company is committed to working with partners on a number of research and development projects aimed at delivering a variety of drugs using Polyolefins and bringing these novel drug delivery systems to market. ...
CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, has announced an expanded portfolio of Polydimethylsiloxane (PDMS) products, empowering researchers with versatile and biocompatible tools for groundbreaking discoveries. ...
Over the past few decades, researchers have been working on developing delivery systems that can reduce side effects while improving efficacy. ...
CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, recently introduced a line of highly efficient mRNA Transfection Reagents with low toxicity for research applications, including the mRNA Transfection Reagent, Stem mRNA Transfection Reagent, and mRNA/gRNA Transfection Reagent. mRNA transfection is the process of ...
CD Bioparticles, a leading manufacturer and supplier of various drug delivery products and services, recently introduced a series of Magnetofection Reagents for gene expression. ...
On top of her strong enthusiasm for applications of AI and NLP technology in clinical decision support, Laurie brings a wealth of first-hand clinical research and patient pre-screening experience. Most recently, Laurie was a Vice President for Clinical Research Services at Roswell Park ...
Vault Health’s decentralized research capabilities will allow Faeth to extend the NEAAR clinical trial beyond physical clinical trial sites to patients living across the country. By combining xCures’ records collection, virtual screening, eConsent and data structuring technology with Vault Health’s state-of-the-art suite of ...
ByxCures
Specifically, Orbit gains access to WuXi AppTec’s expertise in peptide optimisation, peptide production and manufacturing to help its Partners obtain clinically relevant data packs and materials in a rapid timeframe. Orbit will also utilise other capabilities within WuXi AppTec, in particular their expertise in cell line and assay development and ...
With entities based in Belgium, France, Spain and the UK, OncoDNA has built an outstanding network of cancer clinicians-researchers across Europe. The company will act as a primary lab partner, operating C2i’s whole-genome sequencing (WGS) and minimal-residual disease (MRD) cancer monitoring platform for European clinical research projects. ...
Balt, an innovative neurovascular company focused on developing, designing, and manufacturing solutions for treating complex, life-threatening conditions, including stroke, aneurysms, and arteriovenous malformations, today announced the appointment of Jeffrey Sachs as the Company's Chief Legal & Compliance Officer. ...
About Precision for Medicine Precision for Medicine is the first biomarker-driven clinical research services organization supporting life sciences companies in the use of biomarkers essential to targeting patient treatments more precisely and effectively. Precision applies novel biomarker approaches to clinical ...
Establishes Thermo Fisher as a global leader in the attractive and high growth clinical research services industry Adds highly complementary services for the company's fastest growing end market Offers both meaningful cost and revenue synergies which will further accelerate growth Expected to be immediately and significantly accretive to Adjusted Earnings Per Share (EPS)¹ after close ...